Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$167.25 USD

167.25
664,165

-0.02 (-0.01%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $167.18 -0.07 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Charles River (CRL) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.

Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised

by Zacks Equity Research

Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.

Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect

by Zacks Equity Research

Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.

Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?

by Zacks Equity Research

Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.

Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?

by Zacks Equity Research

STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.

Should You Buy Encompass Health (EHC) Ahead of Q1 Earnings?

by Zacks Equity Research

Encompass Health's (EHC) Q1 results are likely to benefit on the back of growing patient volumes and commendable expansion initiatives.

Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?

by Zacks Equity Research

Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.

Henry Schein (HSIC) Gears Up for Q1 Earnings: Factors to Note

by Zacks Equity Research

Henry Schein's (HSIC) first-quarter 2024 results are likely to indicate a strong sales recovery post last year's cybersecurity incident.

Will Acute Care Unit Aid Universal Health's (UHS) Q1 Earnings?

by Zacks Equity Research

Universal Health's (UHS) Q1 results are expected to be aided by growing patient volumes and surgical cases, partly offset by increased expenses.

What's in the Cards for Zimmer Biomet (ZBH) in Q1 Earnings?

by Zacks Equity Research

Within the Hips business, Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery, banking on strategic product launches in the first quarter.

What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?

by Zacks Equity Research

IDEXX Laboratories' (IDXX) first-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.

Nalak Das headshot

5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings

by Nalak Das

We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.

Here's Why You Should Retain Prestige Consumer (PBH) Stock Now

by Zacks Equity Research

The robust strength of Prestige Consumer's (PBH) diversified portfolio bodes well for investors.

ICON (ICLR) Gains From New Offerings, Strategic Acquisitions

by Zacks Equity Research

ICON (ICLR) continues to develop its collaboration and delivery models, invest in technology and enhance its project and program management capabilities.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

The strength of a diversified enterprise, along with robust operational execution, is expected to be reflected in CVS Health's (CVS) first-quarter 2024 results.

Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract

by Zacks Equity Research

Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Favorable Dental business trends and expansion efforts through acquisitions and partnerships bode well for Henry Schein (HSIC).

Labcorp (LH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Labcorp (LH) is anticipated to drive growth in the first quarter of 2024 through base business expansion, integrating acquisitions and partnerships and advancing in science and technology.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.

Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Insulet (PODD) Stock Moves -0.34%: What You Should Know

by Zacks Equity Research

Insulet (PODD) concluded the recent trading session at $177.41, signifying a -0.34% move from its prior day's close.